Gilead Sciences terminates development of magrolimab in blood cancers
Gilead is ending development of magrolimab in blood cancer after an “increased risk of death” was observed in a late-stage trial
Gilead announced that the phase III ENHANCE-3 study is being discontinued in acute myeloid leukemia based on the recommendation of the independent data monitoring committee that had been reviewing top-line data from a planned interim analysis. The analysis showed an increased risk of death when adding magrolimab to the chemotherapy azacitidine and Genentech/AbbVie’s Venclexta, as well as futility. The deaths were caused by infections and respiratory failure.
The FDA has now placed a full clinical hold on the anti-CD47 antibody in myelodysplastic syndromes (MDS) and AML, plus related expanded access programs.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins